Vacchiano, V.
Tonon, C.
Mitolo, M.
Evangelisti, S.
Carbonelli, M.
Liguori, R.
Lodi, R.
Carelli, V.
La Morgia, C. http://orcid.org/0000-0002-4639-8929
Article History
Received: 14 April 2019
Accepted: 17 December 2019
First Online: 30 December 2019
Ethics approval and consent to participate
: Our Ethical Committee approved the study (CE 211/2018/SPER/AUSLBO) and the patient gave written informed consent to participate.
: The patient gave written informed consent for publication.
: Dr. V Vacchiano, Prof C Tonon, Dr. M Mitolo, Dr. S Evangelisti and Prof R Lodi report no disclosures.Dr. M Carbonelli is involved in clinical trials with Santhera Pharmaceuticals (Raxone in Leber’s Hereditary Optic Neuropathy), GenSight Biologics (gene therapy with GS10 in Leber’s Hereditary Optic Neuropathy) and received travel reimbursements from Santhera Pharmaceuticals.Prof Rocco Liguori reports personal fees from Biogen, Sanofi- Genzyme, Argon Healthcare s.r.l., Amicus Therapeutics s.r.l. and Alfasigma for Advisory Board consultancy and Lecture fees from Dynamicom Education, SIMG Service, Adnkronos salute unipersonale s.r.l. and DOC Congress s.r.l. outside the submitted work.Prof V Carelli is involved in clinical trials with Santhera Pharmaceuticals (Raxone in Leber’s Hereditary Optic Neuropathy), GenSight Biologics (gene therapy with GS10 in Leber’s Hereditary Optic Neuropathy) and Stealth BioPharma (Elamipretide in Primary Mitochondrial Myopathy), and received speaker honoraria for educational courses and travel reimbursements from Santhera Pharamceuticals. He is also founded for research program by Stealth Pharmaceuticals, and his research is supported by grants from the Italian Ministry of Health, Telethon, the Emilia Romagna Region, the patient’s organization MITOCON and by private donations.Dr. C La Morgia is involved in clinical trials with Santhera Pharmaceuticals (Raxone in Leber’s Hereditary Optic Neuropathy) and GenSight Biologics (gene therapy with GS10 in Leber’s Hereditary Optic Neuropathy) and received speaker honoraria for educational courses and travel reimbursements from Santhera Pharmaceuticals. Dr. La Morgia is funded by the Ministry of Health grant GR-2013-02358026 and is co-PI for the Ministry of Health grant GR-2016-02361449.